Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
- Conditions
- Resectable Esophageal Cancer
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 40
- Registration Number
- NCT05307835
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-31
- Target Recruit Count
- 71
- Registration Number
- NCT05292417
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
- Conditions
- Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 141
- Registration Number
- NCT05266001
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Benioff Children's Hospital - Oakland, Oakland, California, United States
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 286
- Registration Number
- NCT04936529
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04909515
- Locations
- 🇷🇺
National Medical Research Center Pediatric Hematology, Oncology and Immunology n.a Dmitry Rogachev, Moscow, Russian Federation
🇸🇬ICON Cancer Centre Novena, Singapore, Singapore
🇷🇺Research Institute of Pediatric Oncology ad Hematology of N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 66
- Registration Number
- NCT04892498
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳The Sixth Affiliated Hospital ，Sun Yat-seen University, Guangzhou, China
IBI188 Combination Therapy in Solid Tumors
- Conditions
- OsteosarcomaSolid TumorsLung Adenocarcinoma
- Interventions
- Drug: Cisplatin/Carboplatin
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04861948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Metastatic Solid Cancer Clinical Trial
- Conditions
- Metastatic Cancer
- Interventions
- Procedure: Non-ablative Cryosurgical freezing
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- ImmunSYS, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04739618
- Locations
- 🇺🇸
Vincere Cancer Center, Scottsdale, Arizona, United States
🇺🇸Florida Endovascular and Interventional, Miami Lakes, Florida, United States
A Phase 2 Trial for Patients With Metastatic Solid Cancer
- Conditions
- Metastatic Cancer
- Interventions
- Procedure: Cryosurgical freezing (cryosurgery)
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Rampart Health, L.L.C.
- Target Recruit Count
- 32
- Registration Number
- NCT04713371
- Locations
- 🇺🇸
Ascension Providence Rochester Hospital, Rochester, Michigan, United States
Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia
- Conditions
- Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 362
- Registration Number
- NCT04446052
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.